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Abstract
Objectives: Document progress in HIV-treatment in the Netherlands since 1996 by reviewing changing patterns of cART use
and relating those to trends in patients’ short-term clinical outcomes between 1996 and 2010.
Design and Methods: 1996–2010 data from 10,278 patients in the Dutch ATHENA national observational cohort were
analysed. The annual number of patients starting a type of regimen was quantified. Trends in the following outcomes were
described: i) recovery of 150 CD4 cells/mm3 within 12 months of starting cART; ii) achieving viral load (VL) suppression
#1,000 copies/ml within 12 months of starting cART; iii) switching from first-line to second-line regimen within three years
of starting treatment; and iv) all-cause mortality rate per 100 person-years within three years of starting treatment.
Results: Between 1996 and 2010, first-line regimens changed from lamivudine/zidovudine-based or lamivudine/stavudine-
based regimens with unboosted-PIs to tenofovir with either emtricitabine or lamivudine with NNRTIs. Mortality rates did not
change significantly over time. VL suppression and CD4 recovery improved over time, and the incidence of switching due to
virological failure and toxicity more than halved between 1996 and 2010. These effects appear to be related to the use of
new regimens rather than improvements in clinical care.
Conclusion: The use of first-line cART in the Netherlands closely follows changes in guidelines, to the benefit of patients.
While there was no significant improvement in mortality, newer drugs with better tolerability and simpler dosing resulted in
improved immunological and virological recovery and reduced incidences of switching due to toxicity and virological
failure.
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Introduction
Combination antiretroviral therapy (cART) was first introduced
more than 15 years ago. Since 1996, over twenty new
antiretroviral drugs have been licenced for the treatment of
HIV-infection [1]. A number of clinical trials and studies have
compared specific antiretroviral drugs or regimen types with
respect to selected clinical outcomes [2–12]. However, it remains
unclear how the improved efficacy of new antiretroviral reported
in trials has translated to population-level effectiveness in general
clinical care.
A non-selective database that collects data from all HIV-
infected patients in clinical care in the Netherlands provides a
unique opportunity to record the progress of cART since 1996
across a variety of clinical and non-clinical markers. We aim to use
this dataset to document progress in HIV-treatment by: i)
reviewing the changing patterns of first-line cART regimens
between 1996 and 2010 in the Netherlands; ii) to describe time
trends in a variety of short-term clinical and non-clinical markers;
and iii) to relate new regimens to trends in patients’ short-term
clinical outcomes as a measure of population-level effectiveness.
Methods
Data
ATHENA is a national observational cohort that includes all
HIV-patients followed in 25 designated HIV treatment centres in
the Netherlands since 1996. The design of this cohort has been
described previously [13]. Clinical, biological and immunological
data on HIV-infected patients are collected upon entry and at
each follow-up visit. Anonymised patient data are available on
request and for scientific research purposes only (Ref: www.hiv-
monitoring.nl).
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Patients from the ATHENA cohort were included in this
analysis if they were aged 18 or over, infected with HIV-1, and
diagnosed with HIV from 1st January 1996. Patients were
antiretroviral drug-naı¨ve prior to entering the study and started
cART during follow-up. Women known to have been pregnant
during follow-up were excluded. Data was analyzed up to and
including 31st December 2010. The number of patients in the
analysis was 10 278 patients.
Combination therapy was defined as regimens containing three
or more antiretroviral drugs. Regimen types were classified by
nucleoside reverse transcriptase inhibitor (NRTI) backbone: i)
lamivudine (3TC) and stavudine (d4T); ii) 3TC and zidovudine
(AZT); and iii) tenofovir (TDF) with 3TC or emtricitabine (FTC).
The analysis was further stratified into regimens combined with
either: i) non-nucleoside reverse transcriptase inhibitors (NNRTI);
ii) non-boosted protease inhibitors (PI); or iii) (ritonavir)-boosted-
PIs. Regimens other than those described above were classified as
‘other’ in further analysis. The choice of regimen classification
reflects the main regimen types used between 1996 and 2010 in
the Netherlands.
Clinical outcome was measured using: i) hazard rate of
recovering 150 CD4 cells/mm3 within 12 months of starting
cART; ii) hazard rate of achieving viral load (VL) suppression
#1,000 copies/ml within 12 months of starting cART; iii) the
incidence of switching from first-line to second-line regimen within
three years of starting treatment; and iv) all-cause mortality rate
per 100 person-years within three years of starting treatment. A
threshold of 1,000 copies/ml for VL suppression was chosen to
allow for comparison across the years, due to the changing
detection threshold for VL suppression, from 1,000 copies/ml in
1996 to 20 copies/ml in 2010.
A switch was defined as a change in regimen that included at
least one new antiretroviral drug. Reasons for switching were
classified as: i) toxicity, ii) simplification/new medication becoming
available, iii) virological failure, and iv) other reasons [14].
‘Toxicity’ is defined as the need to change regimen due to
experience of side effects. ‘Simplification/new medication be-
comes available’ is defined as patients switching regimen for a
simpler cART regimen, for example a once-daily regimen, or
because a new cART regimen has become available. ‘Virological
failure’ refers to a switch due to poor virological response,
including resistance. ‘Other reasons’ included pharmacological
reasons, caution, ‘other’ and ‘unknown’ reasons as classified by the
ATHENA cohort. ‘Pharmacologic reason’ refers to an interaction
with co-medication/other drug and ‘caution’ refers to the situation
where patients are starting an additional treatment, for example
chemotherapy, and the physician decides to stop or change a
regimen as the combination of side effects may be too heavy.
Apart from toxicity, simplification/new medication becoming
available, virological failure, and other reasons, there were other
drug-related reasons for switching treatment (compliance (0.66%),
and contra-indication (0.04%)), which were excluded as they
accounted for less than 1% of switches. Date and reasons for
switching are recorded by physicians at follow-up visit when a
patient is prescribed a change in cART regimen.
Statistical analysis
Time-dependent Cox proportional hazard model and Kaplan-
Meier curves were used as time-to-event analysis. Cox regression
analyses were carried out on all four clinical outcomes defined
above. When analysing switching, Cox analysis was limited to
virological failure and toxicity. Follow-up time was defined as
months from the start of treatment until the date of end of follow-
up time, closure of the database (31st December 2010), or the
outcome of interest, whichever occurred first. Follow-up was
divided into three time periods, 1996–2000, 2001–2005, and
2006–2010, early cART, medium cART and late cART period.
Mortality was treated as a censored event in analysis where
mortality was not the outcome of interest. Wald statistics were
used to determine significance of this analysis using a significance
level of 0.05 throughout.
Cox Proportional Hazard analysis were adjusted by sex, age
(divided into 5-year categories,18–22, 23–27 years, etc., the last
category being 78–82 years), CD4 and VL at the start of
treatment, route of HIV transmission (men-who-have-sex-with-
men (MSM), heterosexual, injecting drug use (IDU), and vertical
infection, blood infusion, or unknown), and region of origin.
Categories of regions of origin were Netherlands, Europe
(excluding the Netherlands), Sub-Saharan Africa, and other.
CD4 counts categories were ,200, 201–350, 351–500, and
.501 cells/mm3, and VL categories were ,100,000, 100,000–
1,000,000, and .1,000,000 copies/ml. Analysis of mortality was
further controlled for smoking and cumulative number of AIDS-
defining events, as a proxy for lifestyle and advanced disease.
Dutch-born MSM with a CD4 between 350 and 500 cells/mm3
and RNA below 100,000 copies/ml when starting cART were
used as the reference categories in the Cox model. The reference
regimen type was TDF/3TC or TDF/FTC with a NNRTI. These
references were chosen, as this constitutes the majority of patients
in the cohort, with the CD4 range of current guidelines for
treatment initiation [15]. All the data-analysis was carried out in
SAS v.9.3 (SAS Institute, Cary, North Carolina, USA).
Results
Population Description
Demographic characteristics of the patients are summarized in
Table 1. Overall, of the 10,278 patients 84% were male, 59% were
MSM, and 58% were Dutch-born. 44% of patients had spent a
cumulative time five to ten years on cART, and the mean age was
40 at the start of treatment. 391 patients died within three years of
starting treatment.
cART regimens between 1996 and 2010
The cART regimen types used between 1996 and 2010 are
presented in Figure 1A. A backbone of 3TC/d4T was most
commonly combined with boosted-PIs (n = 248, 39%) or PIs
(n = 225, 35%). 3TC/AZT was most frequently combined with
boosted-PIs (n = 1,272, 38%) or a NNRTI (n = 1,175, 35%), while
TDF/3TC or TDF/FTC was mostly combined with NNRTIs
(n = 3,882, 78%). 16.4% of patients started on regimen types with
other backbones or third components.
Between 1996 and 2010, the number of patients starting
treatment increased. In 1996, 156 patients started on therapy per
year, increasing to around 1,000 patients per year after 2007.
From 1996 to 2004 the majority of patients started on a backbone
of 3TC/AZT (Figure 1B and C). Its use declined steadily after
2001, accounting for less than 10% of NRTI backbone from 2008.
The use of 3TC/d4T ranged from 7% to 36% between 1996 and
2002, and accounted for less than 10% of new prescriptions from
2003. Other backbones or other third components were most
commonly prescribed between 2001 and 2004, accounting for up
to 35.3% or first-line regimes. Since the introduction of TDF in
Europe in 2001, its use as a first-line regimen NRTI backbone
increased steadily. After 2004, TDF/3TC or TDF/FTC-based
regimens constituted for the majority of NRTI-backbones for first-
line in the Netherlands accounting for over 85% of first-line
backbones from 2007. The most frequently used third component
cART in The Netherlands 1996-2010
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from 1996 to 2000 were PIs (45–81% non-boosted PIs, 9–48%
boosted-PIs), and from 2000–2010 were NNRTIs (45–81%)
(Figure 1C).
Clinical outcomes between 1996 and 2010
Mortality. The Kaplan-Meier estimate of the percentage of
deaths at three years was 6.4% (95% CI 5.9–6.9). The short-term
all-cause mortality rate of patients on cART between 1996 and
2010 is presented in Figure 2. Hazards for mortality did not differ
significantly between 1996 and 2010 (Table S1) (p-value = 0.44 for
1996–2000 and p-value = 0.16 for 2001–2005 compared to 2006–
2010).
All-cause mortality was significantly increased in older patients
(HR = 1.27 per 5-year increase in age, 95% CI 1.21–1.33, p-
value,.0001), in patients who had acquired HIV via injecting
drug use compared to MSM (HR = 2.90, 95%CI 1.81–4.64, p-
value,0.0001), in smokers (HR = 1.70, 95% CI 1.11–2.60, p-
value = 0.01), and with increasing cumulative AIDS-defining
events (p-value,0.0001). Patients on regimens of TDF/3TC or
TDF/FTC with boosted-PIs may experience increased risk of
mortality compared to patients on TDF/3TC or TDF/FTC with
NNRTIs (HR = 1.49, 95% CI 1.03–2.15, p-value = 0.04).
CD4 recovery. Between 1996 and 2010 70.4% (95% CI
69.5–71.3) patients reached a CD4 increase of 150 cells/mm3
within 12 months of treatment initiation. The CD4 recovery rate
of 150 cells/mm3 following treatment initiation was significantly
higher in 2006–2010 compared to 2001–2005 (HR = 0.94, 95%
CI 0.88–0.99, p-value = 0.03) (Figure 3A, Table S2). The
difference between periods was not significant when models were
adjusted for cART regimen (p-value = 0.46).
CD4 recovery of 150 cells/mm3 was improved in women
(HR = 1.26, 95% CI 1.14–1.38, p-value,0.0001 for women),
worse in older patients (HR = 0.97 per 5-year increase in age, 95%
CI 0.96–0.99, p-value = 0.0001), patients from Sub-Saharan
Africa compared to Dutch-born (HR = 0.71, 95% CI 0.64–0.78,
p-value,0.0001), and patients who had acquired HIV through
heterosexual contact or injecting drug use compared to MSM
(HR = 0.80, 95%CI 0.74–0.87, p-value,0.0001 and HR = 0.51,
95% CI 0.39–0.67, p-value,0.0001, respectively). CD4 recovery
was also worse in patients who had a CD4 count below 200 cell/
mm3 or above 500 cells/mm3 and VL below 100 000 copies/ml
at the start of treatment (HR = 0.84, 95%CI 0.77–0.92, p-
value = 0.0003 and HR = 0.76, 95%CI 0.65–0.89, p-val-
ue = 0.0004, respectively). Patients on regimens of 3TC/d4T or
TDF/3TC or TDF/FTC with boosted-PIs may experience
improved rates of immunological recovery, compared to patients
on TDF/3TC or TDF/FTC with NNRTIs (HR = 1.30, 95%CI
1.08–1.57, p-value = 0.01 and HR = 1.18, 95%CI 1.07–1.29, p-
value = 0.0006).
Viral Load suppression. The Kaplan-Meier estimate of the
percentage of patients achieving VL suppression ,1,000 copies/
ml by 12 months was 94.7% (95% CI 94.2–95.1). VL suppression
following the start of cART was improved in recent years
(HR = 0.79, 95% CI 0.75–0.84, p-value,0.0001 for 1996–2000
and HR = 0.90, 95% CI 0.86–0.95, p-value,0.0001 for 2001–
2005) (Figure 3B and Table S3). The difference between periods
became non-significant when models were adjusted for cART
regimen type (p-value = 0.07 and p-value = 0.12).
In adjusted analysis, VL suppression was worse in patients non-
Dutch, European patients (HR = 0.90, 95% CI 0.82–0.98, p-
Table 1. Demographic characteristics of the 10,278 patients in the study population by calendar time of treatment initiation.
1996–2000 2001–2005 2006–2010 Total
(N=1,997, 19%) (N=3,190, 31%) (N=5,091, 50%) (N=10,278)
Sex
Men 1,721 86 2,543 80 4,322 85 8,586 84
Women 276 14 647 20 769 15 1,692 16
Mean age (years) at treatment initiation 39 (IQR, 32–44) 39 (IQR, 33–46) 41 (IQR, 34–48) 40 (IQR, 33–47)
Transmission
MSM 1,186 59 1,575 49 3,279 64 6,040 59
Heterosexual 605 30 1,247 39 1,448 28 3,300 32
IDU 70 4 75 2 63 1 208 2
Other/unknown 136 7 293 9 301 6 730 7
Region of origin
The Netherlands 1,188 59 1,643 52 3,136 62 5,947 58
Sub-Saharan Africa 264 13 717 22 647 13 1,628 16
Europe 188 9 230 7 437 9 855 8
Other 357 18 600 19 871 17 1,828 18
Cumulative years on treatment
,1 29 1 76 2 513 10 618 6
1–2 41 2 51 2 1,495 29 1,587 15
3–4 29 1 43 1 1,633 32 1,705 17
5–10 391 20 2,774 87 1,331 26 4,497 44
.10 1,506 75 246 8 119 2 1,871 18
Number of deaths within three years of
treatment initiation
75 4 154 5 162 3 391 4
doi:10.1371/journal.pone.0076071.t001
cART in The Netherlands 1996-2010
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Figure 1. First-line cART regimens. A. First-line cART regimens prescribed in the Netherlands between 1996 and 2010. Relative distribution of
patients starting first-line regimens per year by B. NRTI backbone and C. third cART component.
doi:10.1371/journal.pone.0076071.g001
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value = 0.02), for those who had acquired HIV either via
heterosexual contact or injecting drug use (HR = 0.88, 95% CI
0.82–0.95, p-value = 0.0004 and HR = 0.78, 95% CI 0.64–0.94,
p-value = 0.01), and in patients with a VL above 100,000 copies/
ml at the start of treatment (p-value,0.0001). Regimens of 3TC/
AZT with non-boosted or boosted-PIs, and TDF/3TC or TDF/
FTC with boosted-PIs may be associated with worse rates of VL
suppression (HR = 0.71, 95%CI 0.63–0.81, p-value,0.0001,
HR = 0.82, 95%CI 0.75–0.89, p-value,0.0001, and HR = 0.87,
95% CI 0.81–0.95, p-value = 0.001).
Incidence of switching. During follow-up, 4,481 patients
(44%) switched to second-line. The short-term incidence of
switching, due to virological failure or toxicity, from first-line
regimens has declined between 1996 and 2010 (Figure 4),
suggesting that the duration patients spend on a cART-line before
switching regimens has improved considerably over time. The
incidence of switching due to virological failure, toxicity, and
‘other’ reasons between 2006 and 2010 was less than half that of
1996 to 2000. The incidence of switching due to virological failure
decreased from 4.7 events (95% CI 3.8–5.8) in 1996–2000 to 2.3
events per 100 person-years (95% CI 2.0–2.7) in 2006–2010. The
incidence of toxicity-related switching decreased from 26.3 events
(95% CI 24.1–28.7) in 1996–2000 to 13.5 events per 100 person-
years (95% CI 12.7–14.4) in 2006–2010. In contrast, the incidence
of switching due to simplification/new medication becoming
available increased between 1996 and 2010 from 2.2 events per
100 person-years (95% CI 1.6–2.95) in 1996-2000 to 5.26 events
per 100 person-years (95% CI 4.75–5.81) in 2006–2010.
In models adjusted for cART regimen type, differences between
time periods were not significant (Table 2 and Table 3). The only
exception was the increased incidence of switching due to
virological failure amongst patient who started first-line in 2001–
2005 compared to 2006–2010, which could partly, but not fully,
be attributed to the newer regimens (Table 3).
Older patients and women had an increased risk of toxicity-
driven switch, while patients who acquired HIV via heterosexual
sex had a reduced risk of toxicity-driven switch compared to
MSM. Patients on backbones of 3TC with either d4T or AZT had
an increased risk of toxicity-driven switch compared to patients on
TDF/3TC or TDF/FTC with boosted-PIs. The incidence of
switching due to virological failure was higher in patients from
Sub-Saharan Africa, and with a CD4 count below 200 cells/mm3
and VL above 100,000 copies/ml at the start of treatment.
Patients on regimens of 3TC/d4T or 3TC/AZT with unboosted-
Figure 2. Mortality rate per 100 person-years. The black dotted line is the mortality rate; the grey shaded area represents the 95% confidence-
intervals.
doi:10.1371/journal.pone.0076071.g002
Figure 3. Rates of CD4 recovery and VL suppression. Unadjusted Kaplan-Meier curves for A) Rates of CD4 recovery of 150 cells/mm3 by 12
months and B) Rates of VL suppression to below 1,000 copies/ml by 12 months.
doi:10.1371/journal.pone.0076071.g003
cART in The Netherlands 1996-2010
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PIs had an increased risk of virological failure, while patients on
3TC/AZT or TDF/3TC or TDF/FTC with boosted-PIs had a
decreased risk of virological failure.
Among patients who started treatment between 1996 and 2000,
the three main adverse events leading to a switch in regimen were
gastrointestinal- (36.2% of all toxicity-related stops), hepatological-
(15.2%), and hematological-related (10.1%) (Figure 5). In 2001 to
2005 the side effectsmost commonly resulting in switching were
gastrointestinal (24.9%), neurological/psychological (14.9%), and
hematological (12.9%) toxicity. Finally, between 2006 and 2010
patients most commonly switched regimen due to neurological/
psychological (30.7%), dermatological (16.6%), and gastrointesti-
nal toxicity (15.3%).
Discussion
Between 1996 and 2010, first-line regimens changed from
3TC/AZT-based or d4T/3TC-based regimens with PIs to TDF/
3TC or TDF/FTC with NNRTIs. There was no significant
reduction in short-term mortality between 1996 and 2010 when
controlling for clinical and demographic factors, such as age and
CD4 at start of cART, likely because the greatest impact on short-
term mortality occurred before this, as a consequence of the
introduction of combination therapy [16]. However, there were
improvements in CD4 recovery and VL suppression and overall,
the short-term incidence of switching decreased significantly since
1996, suggesting that the duration patients spend on a cART-line
before switching has improved considerably over time. The
incidence of switching to simpler or newer medication in the
absence of virological failure or toxicity has increased between
1996 and 2010. As far as we can tell these changes in outcomes are
related to new drugs rather than improvements in other aspects of
clinical care. This suggests that the changing pattern of first-line
cART use over time in the Netherlands, which closely follows
changes in guidelines, has done so to the benefit of patients in care.
The pattern of changes in first-line cART regimens in the
Netherlands between 1996 and 2010 parallels changes in Dutch
national treatment guidelines and the publication of a number of
clinical studies [15,17]. A study by the Swiss HIV cohort study
showed that adherence to the national recommendation on cART
regimens was associated with better treatment outcomes between
1998 and 2007 [18]. International collaboration cohorts in
developed countries have looked at time trends of certain clinical
outcomes. The ART cohort collaboration found that while more
patients achieved VL suppression to below 500 copies/ml by 6
months that did not result in a reduction in one-year mortality
between 1995 and 2003. The Swiss HIV cohort study found that
while the one-year incidence of switching did not improve between
2000 and 2005, the proportion of patients that were virological
suppressed did improve and CD4 cell count after start of cART
showed greater increases over calendar time. Mocroft and
colleagues also found no significant change in mortality rates
between the early and late cART era [19]. As reported in other
countries, toxicity remains the main reason for switching [20–23],
although newer regimens are associated with improved tolerability
[4,11,24]. The changes in common side effects resulting in
switching coincide with changes in prescribed regimen types
between 1996 and 2010 [1]. Studies into the different clinical
outcomes have identified similar risk factors. Studies into mortality
also reported age, injecting drug use, smoking and AIDS-defining
events as risk factors for mortality [16,25,26]. Studies into toxicity
found the risk to be increased in women, older patients, and
amongst patients on older regimens, in accordance with previous
work [3–7,23,27–34]. Drug exposure is thought to be influenced
by gender-related pharmacokinetics, while polypharmacy in older
patients has been shown to significantly increased the chance of
serious drug-drug interactions [23,27–30]. As with other studies,
Figure 4. Rate of switching per 100 person-years. Calendar time refers to time of switching.
doi:10.1371/journal.pone.0076071.g004
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our results showed that baseline CD4 count and VL can be a
predictor for virological failure, CD4 recovery and VL suppression
[35–37]. There is no clear explanation why some of the other risk
factors identified affect the risk of certain clinical outcomes. For
example, our results suggested that MSM have higher risk of
toxicity-driven switch compared to heterosexual patients, in
accordance with work by Prosperi and colleagues [38]. This
may be due to different perceptions of side effects [39].
To our knowledge this is the first attempt to document progress
in population-level effectiveness of HIV-treatment in the Nether-
lands since 1996 across a large number of clinical and non-clinical
markers. By using a unique, non-selective dataset to review the
changing patterns of cART use coupled with trends in patients’
short-term clinical outcomes, it provides a valuable insight into
how HIV treatment has changed and the impact this has had on
treatment success. The analysis is limited factors typical of cohort
data. Comparison of rates of VL suppression is limited by our use
Table 2. Adjusted hazard ratio (95% Confidence intervals) of switching from first-line to second-line due to toxicity.
Variables Model 1: Calendar time Model 2: Calendar time and regimen type
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Calendar period
1996–2000 1.53 (1.37–1.71) ,.0001 1.02 (0.84–1.24) 0.83
2001–2005 1.40 (1.27–1.54) ,.0001 1.00 (0.86–1.16) 0.99
2006–2010 [Reference] [Reference]
Demographic
Age
5-year increased from 18 years old 1.04 (1.02–1.06) 0.0007 1.04 (1.02–1.07) 0.001
Sex
Male [Reference] [Reference]
Female 1.36 (1.18–1.56) ,.0001 1.39 (1.19–1.62) ,.0001
Region of Origin
Netherlands [Reference] [Reference]
European 0.86 (0.73–1.02) 0.09 0.87 (0.72–1.04) 0.12
Sub-Saharan Africa 1.04 (0.90–1.21) 0.57 1.02 (0.86–1.19) 0.85
Other 1.01 (0.90–1.13) 0.90 0.99 (0.87–1.12) 0.82
Route of transmission
Heterosexual 1.21 (1.07–1.37) 0.003 0.80 (0.70–0.92) 0.002
MSM [Reference] [Reference]
Injecting Drug Use 0.93 (0.64–1.34) 0.69 0.75 (0.49–1.13) 0.17
Other 1.03 (0.86–1.23) 0.78 0.87 (0.72–1.05) 0.14
Clinical
CD4 cell count at start of cART
CD4,200 0.99 (0.86–1.14) 0.90 0.96 (0.82–1.12) 0.61
CD4 201–350 0.93 (0.81–1.07) 0.30 0.96 (0.82–1.12) 0.57
CD4 351–500 [Reference] [Reference]
CD4.501 1.44 (1.19–1.75) 0.0002 1.24 (0.99–1.56) 0.06
RNA at start of cART
RNA,100 000 [Reference] [Reference]
RNA 100 000–1 000 000 1.05 (0.96–1.15) 0.32 0.97 (0.87–1.07) 0.50
RNA.1 000 000 1.08 (0.88–1.32) 0.47 0.88 (0.69–1.12) 0.29
cART Type
3TC/d4T+PI 2.16 (1.63–2.86) ,.0001
3TC/d4T+Boosted-PI 3.34 (2.59–4.31) ,.0001
3TC/d4T+NNRTI 2.21 (1.50–3.26) ,.0001
3TC/AZT+PI 1.38 (1.08–1.75) 0.01
3TC/AZT+Boosted-PI 2.31 (1.97–2.70) ,.0001
3TC/AZT+NNRTI 1.55 (1.30–1.86) ,.0001
TDF/FTC or TDF/3TC+Boosted-PI 1.16 (0.97–1.39) 0.10
TDF/FTC or TDF/3TC+NNRTI [Reference]
doi:10.1371/journal.pone.0076071.t002
cART in The Netherlands 1996-2010
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of the cut-off of 1,000 copies/ml in the definition of VL
suppression. However, we used it in order to compare trends in
VL suppression from 1996 to 2010. Analysis of CD4 recovery and
VL suppression is restricted by the varying monitoring intervals
amongst patients in clinical care. However, as these intervals have
lengthened since 1996 and most patients will have a CD4 count
and VL test by 12 months; this should not significantly affect the
results. The analysis of mortality is limited by the cohort effect, and
the fact that the risk of mortality may also depend on a number of
factors, such as lifestyle, general health, and co-morbidities, which
are not all routinely collected in the dataset. In the analysis we
could not control for adherence as adherence data is not routinely
collected in ATHENA. Adherence may have improved over time
as drugs have become more tolerable [24] and regimens simpler
[40,41]. This and the grouping of regimens into regimen types,
makes it inappropriate to associate specific clinical outcomes, such
as mortality, to specific regimen types. Consequently, associations
observed, such as the increased mortality hazard in patients on
Table 3. Adjusted hazard ratio (95% Confidence intervals) of switching from first-line to second-line due to virological failure.
Variables Model 1: Calendar time Model 2: Calendar time and regimen type
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Calendar period
1996–2000 1.69 (1.30–2.23) 0.0002 0.83 (0.50–1.35) 0.45
2001–2005 1.81 (1.46–2.25) ,.0001 1.86 (1.31–2.62) 0.001
2006–2010 [Reference] [Reference]
Demographic
Age
5-year increased from 18 years old 0.95 (0.91–1.01) 0.07 0.98 (0.93–1.04) 0.47
Sex
Male [Reference] [Reference]
Female 0.91 (0.67–1.23) 0.53 0.74 (0.52–1.04) 0.08
Region of Origin
Netherlands [Reference] [Reference]
European 0.91 (0.61–1.35) 0.63 0.94 (0.61–1.45) 0.79
Sub-Saharan Africa 1.28 (0.94–1.75) 0.11 1.48 (1.06–2.08) 0.02
Other 1.03 (0.78–1.35) 0.85 1.08 (0.80–1.45) 0.61
Route of transmission
Heterosexual 0.90 (0.69–1.17) 0.42 1.10 (0.82–1.46) 0.54
MSM [Reference] [Reference]
Injecting Drug Use 0.85 (0.37–1.96) 0.71 0.82 (0.30–2.23) 0.69
Other 0.84 (0.57–1.24) 0.37 0.77 (0.49–1.21) 0.25
Clinical
CD4 cell count at start of cART
CD4,200 2.92 (1.83–4.67) ,.0001 3.16 (1.83–5.46) ,.0001
CD4 201–350 1.50 (0.92–2.44) 0.11 1.64 (0.93–2.89) 0.09
CD4 351–500 [Reference] [Reference]
CD4 .501 1.36 (0.66–2.81) 0.40 1.20 (0.50–2.86) 0.69
RNA at start of cART
RNA,100 000 [Reference] [Reference]
RNA 100 000–1 000 000 1.60 (1.27–2.01) ,.0001 1.87 (1.44–2.43) ,.0001
RNA .1 000 000 2.46 (1.68–3.60) ,.0001 3.3 (2.16–5.13) ,.0001
cART Type
3TC/d4T+PI 3.05 (1.79–5.19) ,.0001
3TC/d4T+Boosted-PI 0.87 (0.40–1.90) 0.72
3TC/d4T+NNRTI 1.03 (0.43–2.44) 0.95
3TC/AZT+PI 2.65 (1.65–4.24) ,.0001
3TC/AZT+Boosted-PI 0.60 (0.40–0.92) 0.02
3TC/AZT+NNRTI 0.69 (0.45–1.04) 0.08
TDF/FTC or TDF/3TC+Boosted-PI 0.51 (0.30–0.87) 0.01
TDF/FTC or TDF/3TC+NNRTI [Reference]
doi:10.1371/journal.pone.0076071.t003
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TDF/3TC or TDF/FTC with boosted-PIs compared to NNRTI,
should be interpreted with caution. The use of marginal structural
models may be better suited to carry out this kind of evaluation
[42]. The short follow-up available for patients, who started
treatment in later years, means that the long-term effect of cART
regimen on mortality and toxicity could not be evaluated. The
evaluation of the effect of long-term cART use on long-term
toxicity and mortality will be important questions to address in the
future to ensure the continued high quality standard of care.
The use of first-line cART in the Netherlands closely follows
changes in guidelines, to the benefit of patients. While there was
no significant improvement in mortality, newer drugs with better
tolerability and simpler dosing resulted in improved immunolog-
ical and virological recovery and reduced incidences of switching
due to toxicity and virological failure.
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